Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Legal Names
Legal name
Similar Companies1000
TransCure bioServices
TransCure bioServices offers fee-for-service access to unique R&D platforms for drug profiling and anti-HIV/AIDS therapies.
Sector
Subsector
Location
total rounds
total raised
Presage Biosciences
Presage Biosciences has developed a technology platform to improve the cancer drug development process.
Sector
Subsector
Keywords
Location
total rounds
total raised
ICE Bioscience InC.
IICE Bioscience is an Innovative CRO+ Explorer company specializing in early drug discovery services.
Sector
Subsector
Keywords
total rounds
total raised
ProQinase
ProQinase is a leading contract research company for drug discovery in oncology.
Sector
Subsector
Keywords
Location
M&A Details1
Transaction name
Acquired by
JSR Life Sciences
announced date
Financials
Funding Rounds6
Number of Funding Rounds
Money Raised
Their latest funding was raised on 23.05.2014. Their latest investor Qiming Venture Partners. Their latest round Series D
Majuven
Majuven is a Singapore-based venture capital firm that invests in high-growth science and technology-intensive Asian private businesses.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Qiming Venture Partners
Qiming Venture Partners is a leading China-based venture capital firm that invests in technology, consumer, and healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Lilly Asia Ventures
Lilly Asia Ventures is a venture capital firm that invests in life sciences and healthcare companies in Asia, particularly China.
Sector
Subsector
Location
count Of Investments
count Of Exists
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Argonaut Private Equity
Argonaut Private Equity is a global private equity fund that builds emerging market leaders.
Sector
Subsector
Location
count Of Investments
count Of Exists
Qiming Venture Partners
Qiming Venture Partners is a leading China-based venture capital firm that invests in technology, consumer, and healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
CDIB Capital
CDIB Capital International Corporation is the overseas investment arm of China Development Financial.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
CID Group
The CID Group is a private equity and venture capital firm based in Shanghai and Taipei that invests in early-stage Chinese companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors8
Number of lead investors
Number of investors
Qiming Venture Partners
Qiming Venture Partners is a leading China-based venture capital firm that invests in technology, consumer, and healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Nisa Leung
Nisa Leung is a Managing Partner of Qiming Venture Partners and leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages over USD 5.9 billion in assets and investment in over 380 companies. Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital. She currently sits on the board of Gan & Lee (SSE:603087), Zai Lab (NASDAQ:ZLAB; HKSE:9688), Venus MedTech (HKSE:2500), dMed, CanSino Biologics (SSE:688185; HKSE:6185), Chain Medical Labs, New Horizon Health (SEHK:6606), Berry Oncology, Broncus, Valgen, Insilico Medicine among others. Her other investments include Aeonmed Medical, Berry Genomics (SZSE:000710), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Kira Pharmaceutical, LIH, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, VR Medical, Wuxi Leiming, MEDx, Cure Genetics, SinoCell Tech (SSE:688520), Apollomics, Sino United, Schrödinger (NASDAQ:SDGR) and Jacobio (SEHK:1167) among others. Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019 and 2020, named Top 3 Best Female Venture Capitalist in China by Forbes in 2018 and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and Hong Kong Palace Museum.
current job
CDIB Capital
CDIB Capital International Corporation is the overseas investment arm of China Development Financial.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Nancy T. Chang
Nancy T. Chang, Ph.D. has served as a Director at Ansun since 2011. Since 2007, Dr. Chang has served as the President of Apex Enterprises, Inc., an investment management company with a major focus on healthcare investments. From 2007 to 2012, she was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors L.L.C. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine, and before that, she worked at the Roche Institute of Molecular Biology. She has served on the boards of a number of companies, including Charles River Laboratories International, Inc., Applied Optoelectronics Inc. and is currently a member of the board of directors of SciClone Pharmaceuticals, Inc. In addition, Dr. Chang was a member of the board of directors at the Biotechnology Industry Organization (BIO) and BioHouston. Dr. Chang also was a Director at the Federal Reserve Bank in the Dallas Houston Branch, and was a Director for Project Hope. She has published more than 35 papers on topics ranging from monoclonal antibodies to HIV and holds seven patents. Dr. Chang received her Doctorate in Biological Chemistry from Harvard University.
current job
count Of Investments
Acquisitions4
Indivumed - IndivuServ acquired by Crown Bioscience
acquirer
date
type
Indivumed - IndivuServ
Indivumed's IndivuServ offers a combination of biospecimens, clinical information, and expertise.
Sector
Subsector
Keywords
Location
OcellO acquired by Crown Bioscience
acquirer
date
type
OcellO
OcellO offers innovative CRO services for drug discovery that improve lead development efficiency.
Sector
Subsector
Keywords
Location
PreClinOmics acquired by Crown Bioscience
acquirer
date
type
PreClinOmics
PreClinOmics, Inc. is a preclinical company that conducts early research in cardiovascular and metabolic diseases.
Sector
Subsector
Location
People
Founders1
Employee Profiles45
Michael Boice
Executive Director New Product Development
Crystal Falco
Product Management, Cell Line Derived In vitro and In vivo
Yuki Maves
Senior manager, scientific product marketing
Erich Dagnal
Director, corporate development and strategy
Alexandra Xu
Director, corporate legal counsel and data privacy officer
Activity
Recent News4
The graph reveals the ratio (%) of positive news articles in a chosen time range